Clinical evaluation of clobetasone butyrate: a comparative study of its effects in postoperative inflammation and on intraocular pressure.
Clobetasone butyrate, a new corticosteroid with a high topical activity, has been compared with prednisolone phosphate and a placebo in the treatment of inflammation following cataract extraction. These 2 steroids were more effective in relieving postoperative inflammation than placebo (P less than 0.05), though no obvious clinical differences between the 2 compounds emerged from this investigation. However, a single-blind comparative study against betamethasone phosphate in patients suspected of having steroid-induced glaucoma showed that, while betamethasone phosphate significantly raised intraocular pressure, clobetasone butyrate had only a minimal effect, and this difference was statistically significant (P less than 0.02).
D000287:Administration, Topical; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001623:Betamethasone / Q000031:analogs & derivatives* / Q000494:pharmacology; D002387:Cataract Extraction / Q000009:adverse effects*; D002986:Clinical Trials as Topic; D002990:Clobetasol / Q000494:pharmacology / Q000627:therapeutic use*; D004311:Double-Blind Method; D005128:Eye Diseases / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006801:Humans; D007249:Inflammation / Q000209:etiology; D007429:Intraocular Pressure / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D011239:Prednisolone
D000893:Anti-Inflammatory Agents; D001623:Betamethasone; D011239:Prednisolone; D002990:Clobetasol